Apogee Therapeutics/$APGE
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Apogee Therapeutics
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Ticker
$APGE
Sector
Primary listing
Employees
196
Headquarters
Website
APGE Metrics
BasicAdvanced
$4.3B
-
-$4.36
1.52
-
Price and volume
Market cap
$4.3B
Beta
1.52
52-week high
$64.87
52-week low
$26.20
Average daily volume
872K
Financial strength
Current ratio
15.863
Quick ratio
15.619
Long term debt to equity
0.985
Total debt to equity
1.68
Profitability
EBITDA (TTM)
-282.332
Effective tax rate (TTM)
-0.09%
Management effectiveness
Return on assets (TTM)
-25.26%
Return on equity (TTM)
-38.41%
Valuation
Price to book
6.38
Price to tangible book (TTM)
6.38
Price to free cash flow (TTM)
-15.449
Free cash flow yield (TTM)
-6.47%
Free cash flow per share (TTM)
-4.084
Growth
Earnings per share change (TTM)
57.55%
Bulls say / Bears say
APG777’s Phase 2 APEX Part A trial achieved all its main and key secondary goals, showing a 71.0% decline in Eczema Area and Severity Index (EASI) at Week 16, highlighting the drug’s strong effectiveness in moderate-to-severe atopic dermatitis (Nasdaq).
The APEX Part A data indicate that APG777 may offer best-in-class maintenance, with dosing every three to six months compared to bi-weekly regimens, a notable advance that could improve patient adherence and differentiate the product in the market (Nasdaq).
Canaccord Genuity maintained its Buy rating and set an $89.00 price target after the Phase 2 results, referencing the well-established IL-13 mechanism and strong pharmacokinetic/pharmacodynamic data, suggesting over 100% potential upside from current levels (Investing.com).
Data summarised monthly by Lightyear AI. Last updated on 8 Nov 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Apogee Therapeutics stock?
Apogee Therapeutics (APGE) has a market cap of $4.3B as of November 13, 2025.
What is the P/E ratio for Apogee Therapeutics stock?
The price to earnings (P/E) ratio for Apogee Therapeutics (APGE) stock is 0 as of November 13, 2025.
Does Apogee Therapeutics stock pay dividends?
No, Apogee Therapeutics (APGE) stock does not pay dividends to its shareholders as of November 13, 2025.
When is the next Apogee Therapeutics dividend payment date?
Apogee Therapeutics (APGE) stock does not pay dividends to its shareholders.
What is the beta indicator for Apogee Therapeutics?
Apogee Therapeutics (APGE) has a beta rating of 1.52. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.